Business
IM Cannabis Provides Update on Adjupharm Business Developments in Germany
IMC Subsidiary, Adjupharm, Signs New Supply Agreement to Expand Product PortfolioAgreement with Northern Green Canada Strengthens Adjupharm's Position as
About this update from Im Cannabis Corp.
[{"type":"text","content":"IMC Subsidiary, Adjupharm, Signs New Supply Agreement to Expand Product PortfolioAgreement with Northern Green Canada Strengthens Adjupharm's Position as Leading EU GMP-Certified Medical Cannabis Distributor in EuropeTORONTO, ON, BAD OLDESLOE, GERMANY and GLIL YAM, ISRAEL / ACCESSWIRE / April 12, 2021 / IM Cannabis Corp. (\"IMC\" or the \"Company\") (CSE:IMCC)(NASDAQ:IMCC), a multi-country operator (\"MCO\") in the medical and adult-use recreational cannabis sector with operations in Canada, Israel and Germany, today provided a corporate update on its operations in Germany, including the expansion of its product portfolio following the signing of a new supply agreement.IMC's German-based subsidiary and EU GMP-certified medical cannabis distributor, Adjupharm GmbH (\"Adjupharm\"), serves as the Company's distribution hub for EU expansion. It has binding sales agreements with distributions partners, reaching over 6,000 pharmacies. Adjupharm recently signed a supply agreement with Northern Green Canada (\"NGC\") to provide Adjupharm with EU GMP-certified medical cannabis.\"As a patient-first company and trusted partner of the global medical community, IMC is laser-focused on partnering with the best-in-class producers of the highest-quality medical cannabis strains to satisfy the requirements of our German patients,\" said Oren Shuster, CEO of IMC. \"As a leading global operator, IMC sets the standard for providing exceptional cannabis products. The deep knowledge of the medical cannabis industry that we've gained over the past 10 years allows us to adhere to the highest standards.\"Headquartered in Ontario, Canada, NGC is the first privately owned Canadian-licensed cannabis producer to achieve EU GMP certification and currently operates a 2,500 square-meter indoor growing and processing facility.\"Our strategic agreement with NGC supports Adjupharm's momentum and mission,\" added Richard Balla, CEO of Adjupharm. \"Our first priority has always been to address the growing demand from both patients and physicians for the best medical cannabis available. As Adjupharm strives to meet these increasing demands, the supply agreement with NGC allows us to strengthen our distribution network and grow our product portfolio, positioning us to remain ahead of the curve.\"IMC also announced today that the Company and Zur Rose Pharma GmbH have ...